fbpx

Multiple Endocrine Neoplasia Type 2 (MEN2)

Updated : September 3, 2022





Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

 
 

liraglutide 

Not safe and efficacious for children less than 10 years
For more than 10 years (Victoza only)- 0.6 mg subcutaneously daily
1 week later- 0.6 mg each day. Increase the dose to 1.2 mg/day if additional glycemic level is desired



 

Media Gallary

References

Multiple Endocrine Neoplasia Type 2 (MEN2)

Updated : September 3, 2022




liraglutide 

Not safe and efficacious for children less than 10 years
For more than 10 years (Victoza only)- 0.6 mg subcutaneously daily
1 week later- 0.6 mg each day. Increase the dose to 1.2 mg/day if additional glycemic level is desired